Abstract:Senescence refers to a cellular state marked by irreversible cell cycle arrest and the secretion of pro-inflammatory and tissue-remodeling factors. The senescence associated secretory phenotype (SASP) impacts the tissue microenvironment and provides cues for the immune system to eliminate senescent cells (SCs). Cellular senescence has a dual nature; it can be beneficial during embryonic development, tissue repair, and tumor suppression, but it can also be detrimental in the context of chronic stress, persistent tissue injury, together with an impairment in SC clearance. Recently, the accumulation of SCs has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH), a progressive condition affecting the pre-capillary pulmonary arterial bed. PAH is characterized by endothelial cell (EC) injury, inflammation, and proliferative arterial remodeling, which leads to right heart failure and premature mortality. While vasodilator therapies can improve symptoms, there are currently no approved treatments capable of reversing the obliterative arterial remodeling. Ongoing endothelial injury and dysfunction is central to the development of PAH, perpetuated by hemodynamic perturbation leading to pathological intimal shear stress. The precise role of senescent ECs in PAH remains unclear. Cellular senescence may facilitate endothelial repair, particularly in the early stages of disease. However, in more advanced disease the accumulation of senescent ECs may promote vascular inflammation and occlusive arterial remodeling. In this review, we will examine the evidence that supports a role of endothelial cell senescence to the pathogenesis of PAH. Furthermore, we will compare and discuss the apparent contradictory outcomes with the use of interventions targeting cellular senescence in the context of experimental models of pulmonary hypertension. Finally, we will attempt to propose a framework for the understanding of the complex interplay between EC injury, senescence, inflammation and arterial remodeling, which can guide further research in this area and the development of effective therapeutic strategies.

Cellular senescence in the pathogenesis of pulmonary arterial hypertension: the good, the bad and the uncertain

Potential Role of Cellular Senescence in Pulmonary Arterial Hypertension

Epigenetic Regulation of Pulmonary Arterial Hypertension

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

Endothelial senescence mediates hypoxia-induced vascular remodeling by modulating PDGFB expression

Cellular Senescence in the Lung: The Central Role of Senescent Epithelial Cells

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Cellular senescence impairs the reversibility of pulmonary arterial hypertension

Understanding the Intricacies of Cellular Senescence in Atherosclerosis: Mechanisms and Therapeutic Implications

Cell Death in Pulmonary Arterial Hypertension

Cellular senescence: from physiology to pathology

Pulmonary Artery Smooth Muscle Cell Senescence Promotes the Proliferation of PASMCs by Paracrine IL-6 in Hypoxia-Induced Pulmonary Hypertension

Prolonged WNT/ß-catenin signaling induces cellular senescence in aging and pulmonary fibrosis

Cellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy

Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

Cellular Senescence in Cardiovascular Diseases: From Pathogenesis to Therapeutic Challenges

Cellular Senescence in Cardiovascular Diseases: A Systematic Review

Cellular senescence: the good, the bad and the unknown

Stem/Progenitor Cells And Pulmonary Arterial Hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Emerging role of cellular senescence in normal lung development and perinatal lung injury